Skip to main content

Advertisement

SpringerLink
Log in

Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors

Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

To assess the efficacy of whole-brain radiotherapy (WBRT) and prognostic factors in leptomeningeal carcinomatosis (LMC) of non-small-cell lung cancer (NSCLC) patients. WBRT records of 51 LMC patients confined to brain were reviewed. Eligible patients had squamous-cell carcinoma (SCC) or adenocarcinoma, and Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0–3. The WBRT was either 20 or 30 Gray. The primary and secondary objectives were to determine overall survival (OS) and prognostic factors for improved treatment response, respectively. Median age was 53 years (range 39–68), 58.8 % had SCC, 74.5 % had ECOG PS 1–2, and 70.6 % had LMC accompanied by parenchymal brain metastases (BM). The median follow-up was 4.1 months (range 0.7–14.4); all patients died due to disease progression. Median OS was 3.9 months (95 % CI 3.3–4.5) with 6 and 12 month estimates of 19.6 and 5.9 %, respectively. Evaluation of prognostic factors revealed that patients with ECOG 1, longer time to LMC (TT-LMC) from NSCLC diagnosis (>11.3 months), and absence of parenchymal BM had significantly superior OS than those patients with ECOG 2 (p = 0.01) or 3 (p < 0.001), TT-LMC < 11.3 months (p = 0.001), and parenchymal BM (p = 0.012). Median OS of 3.9 months after WBRT appeared to confirm the poor prognosis of LMC. WBRT might be most effective for patients with favorable PS, longer TT-LMC, and no accompanying BM. Therefore, we identified ECOG PS 1, TT-LMC > 11.3 months, and no BM as independent prognosticators for better response to WBRT in NSCLC patients with LMC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P (1988) Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6(9):1474–1480

    CAS  PubMed  Google Scholar 

  2. Kocher M, Wittig A, Piroth MD, Treuer H, Seegenschmiedt H, Ruge M et al (2014) Stereotactic radiosurgery for treatment of brain metastases. a report of the DEGRO working group on stereotactic radiotherapy. Strahlenther Onkol 190(6):521–532

    Article  PubMed  Google Scholar 

  3. Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM et al (2012) Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 76(3):387–392

    Article  PubMed  Google Scholar 

  4. Chowdhary S, Chamberlain M (2005) Leptomeningeal metastases: current concepts and management guidelines. J Natl Compr Canc Netw 3(5):693–703

    PubMed  Google Scholar 

  5. Chamberlain MC, Kormanik P (1998) Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55(4):506–512

    Article  CAS  PubMed  Google Scholar 

  6. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR et al (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7(2):382–385

    Article  PubMed  Google Scholar 

  7. Chamberlain MC (2010) Leptomeningeal metastasis. Curr Opin Oncol 22(6):627–635

    Article  PubMed  Google Scholar 

  8. Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49(4):759–772

    Article  CAS  PubMed  Google Scholar 

  9. Groves MD (2010) New strategies in the management of leptomeningeal metastases. Arch Neurol 67(3):305–312

    Article  PubMed  Google Scholar 

  10. Hitchins RN, Bell DR, Woods RL, Levi JA (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5(10):1655–1662

    CAS  PubMed  Google Scholar 

  11. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11(3):561–569

    CAS  PubMed  Google Scholar 

  12. Boogerd W, vd Sande JJ, Moffie D (1988) Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51(10):1277–1283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yavuz AA, Topkan E, Onal C, Yavuz MN (2008) Prophylactic cranial irradiation in locally advanced non-small cell lung cancer: outcome of recursive partitioning analysis group 1 patients. J Exp Clin Cancer Res 27:80

    Article  PubMed Central  Google Scholar 

  14. Hermann B, Hultenschmidt B, Sautter-Bihl ML (2001) Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis. Strahlenther Onkol 177(4):195–199

    Article  CAS  PubMed  Google Scholar 

  15. Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N et al (2014) Central nervous system cancers, version 2.2014. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12:1517–1523

    PubMed  PubMed Central  Google Scholar 

  16. Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY et al (2013) Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 8(5):599–605

    Article  CAS  PubMed  Google Scholar 

  17. Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM et al (2013) Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 8(2):185–191

    Article  PubMed  Google Scholar 

  18. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK et al (2013) Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31(7):895–902

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25(2):103–119

    Article  CAS  PubMed  Google Scholar 

  20. Chamberlain MC, Kormanik PA (1997) Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 54(11):1364–1368

    Article  CAS  PubMed  Google Scholar 

  21. Palma JA, Fernandez-Torron R, Esteve-Belloch P, Fontes-Villalba A, Hernandez A, Fernandez-Hidalgo O et al (2013) Leptomeningeal carcinomatosis: prognostic value of clinical, cerebrospinal fluid, and neuroimaging features. Clin Neurol Neurosurg 115(1):19–25

    Article  PubMed  Google Scholar 

  22. Bruna J, Gonzalez L, Miro J, Velasco R, Gil M, Tortosa A et al (2009) Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115(2):381–389

    Article  PubMed  Google Scholar 

  23. Gani C, Muller AC, Eckert F, Schroeder C, Bender B, Pantazis G et al (2012) Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors. Strahlenther Onkol 188(2):148–153

    Article  CAS  PubMed  Google Scholar 

  24. Waki F, Ando M, Takashima A, Yonemori K, Nokihara H, Miyake M et al (2009) Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 93(2):205–212

    Article  PubMed  Google Scholar 

  25. Gong L, Xiong M, Huang Z, Miao L, Fan Y (2015) Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations. Lung Cancer 89(3):268–273

    Article  PubMed  Google Scholar 

  26. Thunnissen E et al (2015) Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer 89(3):255–261

    Article  PubMed  Google Scholar 

  27. Ahn JH, Lee SH, Kim S, Joo J, Yoo H, Lee SH et al (2012) Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection. J Neurosurg 116(5):984–993

    Article  PubMed  Google Scholar 

  28. Huang AJ, Huang KE, Page BR, Ayala-Peacock DN, Lucas JT Jr, Lesser GJ et al (2014) Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery. J Neurooncol 120(1):163–169

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Baskent University Adana Medical Faculty, Adana, Turkey

    Yurday Ozdemir, Berna Akkus Yildirim & Erkan Topkan

Authors
  1. Yurday Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Berna Akkus Yildirim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erkan Topkan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yurday Ozdemir.

Ethics declarations

Conflict of interest

None declared.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ozdemir, Y., Yildirim, B.A. & Topkan, E. Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors. J Neurooncol 129, 329–335 (2016). https://doi.org/10.1007/s11060-016-2179-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-016-2179-9

Keywords

Search

Navigation